ACRS - Aclaris Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Aclaris Therapeutics, Inc.

640 Lee Road
Suite 200
Wayne, PA 19087
United States
484-324-7933
http://www.aclaristx.com

Sector
Industry
Full Time Employees169

Key Executives

NameTitlePayExercisedYear Born
Dr. Neal S. Walker D.O.Co-Founder, CEO, Pres & Director782.76kN/A1970
Dr. David N. GordonChief Medical Officer434.92kN/A1969
Mr. Frank RuffoCo-Founder, CFO & TreasurerN/AN/A1966
Ms. Kamil Ali-Jackson Esq., J.D.Co-Founder, Chief Legal Officer, Chief Compliance Officer & Sec.N/AN/A1959
Dr. Michael Steven Tung M.D.Sr. VP of Corp. Strategy/Investor RelationsN/AN/A1974
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 MK-2 pathway oral inhibitor for the treatment of rheumatoid arthritis, psoriasis, hidradenitis suppurativa, cryopyrin-associated periodic syndrome, and pyoderma gangrenosum; ATI-1777 JAK1/JAK3 soft topical inhibitor for atopic dermatitis, vitiligo, and alopecia areata; ITK/JAK3 soft topical and oral inhibitors to treat psoriasis and inflammatory diseases; MK-2 pathway oral inhibitor for oncology; and ITK-JAK3 oral gut-restricted inhibitor for ulcerative colitis/Crohn's disease. Further, it provides contract research laboratory services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.

Corporate Governance

Aclaris Therapeutics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.